文献速递胸部肿瘤头颈与中枢神经肿瘤

洛拉替尼对ALK阳性晚期非小细胞肺癌颅内疗效与安全性的III期CROWN研究事后分析

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
PubMed 文献 · J Clin Oncol · 2022-05-23

III期CROWN研究事后分析显示,洛拉替尼一线治疗ALK阳性晚期非小细胞肺癌,在基线有或无脑转移患者中均较克唑替尼改善无进展生存期并降低中枢神经系统进展累积发生率。35%患者发生中枢神经系统不良事件,多为1级,半数经干预或剂量调整后缓解。

要点

  • 基线有脑转移者12个月PFS率洛拉替尼78% vs 克唑替尼22%,无脑转移者78% vs 45%。
  • 12个月CNS进展累积发生率:有脑转移者洛拉替尼7% vs 克唑替尼72%,无脑转移者1% vs 18%。
  • 洛拉替尼组35%发生CNS不良事件,多为1级;56%已缓解,38%未缓解,多数无需干预。

核心结论

  • 一线洛拉替尼较克唑替尼改善晚期ALK阳性非小细胞肺癌患者的PFS结局并降低CNS进展,无论基线有无脑转移。

研究设计与样本

  • III期CROWN研究事后分析, eligible患者按1:1随机分配至一线洛拉替尼100 mg每日一次或克唑替尼250 mg每日两次,不允许交叉。
  • 肿瘤评估包括CNS磁共振成像,筛查时进行,之后每8周一次;定期进行患者报告结局评估。

主要发现

  • 基线有脑转移患者12个月PFS率洛拉替尼78% vs 克唑替尼22%;无脑转移患者78% vs 45%。
  • 12个月CNS进展累积发生率:有脑转移患者洛拉替尼7% vs 克唑替尼72%;无脑转移患者1% vs 18%。
  • 洛拉替尼组35%患者发生CNS不良事件,多数为1级;CNS不良事件发生未导致患者报告生活质量出现有临床意义的差异。
  • 分析时56%的CNS不良事件已缓解(33%未干预,17%经洛拉替尼剂量调整),38%未缓解;多数无需干预。
  • 洛拉替尼剂量调整未显著影响PFS。

关键数值与推荐

  • 洛拉替尼一线给药方案为100 mg每日一次;克唑替尼为250 mg每日两次。
  • 肿瘤评估包括CNS磁共振成像,筛查时及之后每8周一次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lorlatinib significantly improved progression-free survival (PFS) versus crizotinib and showed robust intracranial activity in patients with previously untreated advanced ALK-positive non-small-cell lung cancer (NSCLC) in the phase III CROWN trial. Here, we report post hoc efficacy outcomes in patients with and without brain metastases at baseline, and present data on the incidence and management of CNS adverse events (AEs) in CROWN. METHODS: Eligible patients were randomly assigned 1:1 to first-line lorlatinib (100 mg once daily) or crizotinib (250 mg twice a day); no crossover between treatment arms was permitted. Tumor assessments, including CNS magnetic resonance imaging, were performed at screening and then at 8-week intervals. Regular assessments of patient-reported outcomes were conducted. RESULTS: PFS by blinded independent central review was improved with lorlatinib versus crizotinib in patients with and without brain metastases at baseline (12-month PFS rates: 78% v 22% and 78% v 45%, respectively). Lorlatinib was associated with lower 12-month cumulative incidence of CNS progression versus crizotinib in patients with (7% v 72%) and without (1% v 18%) brain metastases at baseline. In total, 35% of patients had CNS AEs with lorlatinib, most of grade 1 severity. Occurrence of CNS AEs did not result in a clinically meaningful difference in patient-reported quality of life. At analysis, 56% of CNS AEs had resolved (33% without intervention; 17% with lorlatinib dose modification), and 38% were unresolved; most required no intervention. Lorlatinib dose modification did not notably influence PFS. CONCLUSION: First-line lorlatinib improved PFS outcomes and reduced CNS progression versus crizotinib in patients with advanced ALK-positive non-small-cell lung cancer with or without brain metastases at baseline. Half of all CNS AEs resolved without intervention or with lorlatinib dose modification.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Solomon BJ, Bauer TM, Ignatius Ou SH, et al. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. J Clin Oncol. 2022. PMID: 35605188. doi:10.1200/JCO.21.02278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。